BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
8/19/2026 1:55:09 AM | Browse: 49 | Download: 214
Publication Name World Journal of Gastroenterology
Manuscript ID 117240
Country Austria
ISSN 1007-9327 (print) and 2219-2840 (online)
Open Access This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution-NonCommercial (CC BY-NC 4.0) license. No commercial re-use. See Permissions. Published by Baishideng Publishing Group Inc.
Copyright ©Takeda Development Center Americas Inc 2026. No commercial re-use. See Permissions. Published by Baishideng Publishing Group Inc.
Article Reprints For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website http://www.wjgnet.com
Category Gastroenterology & Hepatology
Manuscript Type Minireviews
Article Title Real-world inflammatory bowel disease-modification outcomes: A narrative review
Manuscript Source Unsolicited Manuscript
All Author List Neeraj Narula, Shashi Adsul and Walter Reinisch
ORCID
Author(s) ORCID Number
Neeraj Narula http://orcid.org/0000-0002-1536-8436
Walter Reinisch http://orcid.org/0000-0002-2088-091X
Funding Agency and Grant Number
Corresponding Author Walter Reinisch, MD, PhD, Department of Medicine III, Division for Gastroenterology and Hepatology, Medical University of Vienna, Währinger Gürtel 18-20, Vienna A-1090, Austria. walter.reinisch@meduniwien.ac.at
Key Words Crohn’s disease; Disease modification; Inflammatory bowel disease; Real-world evidence; Standard protocol items: Recommendations for interventional trials consensus; Ulcerative colitis
Core Tip The standard protocol items: Recommendations for interventional trials (SPIRIT) consensus has recommended disease-modification endpoints for use in clinical trials in patients with inflammatory bowel disease (IBD) to help determine if this approach can prevent disease progression. Before such studies are conducted, real-world evidence can be informative. This review of real-world studies utilizing the SPIRIT consensus endpoints identified considerable gaps in the use of these recommended disease-modification endpoints. Therefore, there remains a need to incorporate SPIRIT recommended disease-modification endpoints in prospective real-world studies in patients with IBD receiving advanced treatments.
Publish Date 2026-08-19 01:55
Citation

Narula N, Adsul S, Reinisch W. Real-world inflammatory bowel disease-modification outcomes: A narrative review. World J Gastroenterol 2026; 32(34): 117240

URL https://www.wjgnet.com/1007-9327/full/v32/i34/117240.htm
DOI https://doi.org/10.3748/wjg.117240
Full Article (PDF) WJG-32-117240-with-cover.pdf